3-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;tris(6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-1,3,5-triazine-2,4-dione)
C77H72N58O8 — CID 158878390
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;tris(6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-1,3,5-triazine-2,4-dione)
3-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;tris(6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-1,3,5-triazine-2,4-dione) (PubChem CID 158878390) has the molecular formula C77H72N58O8 and a molecular weight of 1937.82 g/mol. Its IUPAC name is 3-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;tris(6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-1,3,5-triazine-2,4-dione).
Molecular Properties
| Compound Name | 3-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;tris(6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-1,3,5-triazine-2,4-dione) |
|---|---|
| PubChem CID | 158878390 |
| Molecular Formula | C77H72N58O8 |
| Molecular Weight | 1937.82 g/mol |
| Exact Mass | 1936.70 |
| IUPAC Name | 3-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-pyrazin-2-one;tris(6-[5-amino-3-methyl-4-[(5-methyl-2-pyridin-2-yl-1,2,4-triazol-3-yl)diazenyl]pyrazol-1-yl]-1H-1,3,5-triazine-2,4-dione) |
| SMILES | Cc1nc(/N=N/c2c(C)nn(-c3cncc(=O)[nH]3)c2N)n(-c2ccccn2)n1.Cc1nc(/N=N/c2c(C)nn(-c3nc(=O)[nH]c(=O)[nH]3)c2N)n(-c2ccccn2)n1.Cc1nc(/N=N/c2c(C)nn(-c3nc(=O)[nH]c(=O)[nH]3)c2N)n(-c2ccccn2)n1.Cc1nc(/N=N/c2c(C)nn(-c3nc(=O)[nH]c(=O)[nH]3)c2N)n(-c2ccccn2)n1.Cc1nc(/N=N/c2c(C)nn(-c3ncc[nH]c3=O)c2N)n(-c2ccccn2)n1 |
| InChI | InChI=1S/2C16H15N11O.3C15H14N12O2/c1-9-14(15(17)26(24-9)12-7-18-8-13(28)21-12)22-23-16-20-10(2)25-27(16)11-5-3-4-6-19-11;1-9-12(13(17)27(24-9)14-15(28)20-8-7-19-14)22-23-16-21-10(2)25-26(16)11-5-3-4-6-18-11;3*1-7-10(11(16)27(24-7)12-19-14(28)21-15(29)20-12)22-23-13-18-8(2)25-26(13)9-5-3-4-6-17-9/h3-8H,17H2,1-2H3,(H,21,28);3-8H,17H2,1-2H3,(H,20,28);3*3-6H,16H2,1-2H3,(H2,19,20,21,28,29)/b5*23-22+ |
| InChIKey | JCSOEUGLGKESPI-NTTLOHLHSA-N |
| XLogP | 3.79 |
| TPSA | 888.13 Ų |
| H-Bond Donors | 13 |
| H-Bond Acceptors | 58 |
| Rotatable Bonds | 20 |
| Heavy Atoms | 143 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1937.82 |
| LogP ≤ 5 | 3.79 |
| H-Bond Donors ≤ 5 | 13 |
| H-Bond Acceptors ≤ 10 | 58 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'azo_A(324)', 'substructure': 'N/A'}, {'alert_name': 'diazo_group', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158878390 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.